Previous Article | Next Article ![]()
Journal of Virology, August 2001, p. 7339-7350, Vol. 75, No. 16
Laboratory of Molecular Medicine, Children's
Hospital, Boston, Massachusetts 021151;
Departments of Microbiology and Immunology and of Medicine,
Stanford University School of Medicine, Stanford, California 94305;
the VA Palo Alto Health Care System, Palo Alto, California
943042; and Howard Hughes Medical
Institute and the Department of Molecular and Cellular Biology,
Harvard University, Cambridge, Massachusetts
021383
Received 29 January 2001/Accepted 16 May 2001
Rotavirus particles are activated for cell entry by trypsin
cleavage of the outer capsid spike protein, VP4, into a hemagglutinin, VP8*, and a membrane penetration protein, VP5*. We have purified rhesus
rotavirus VP4, expressed in baculovirus-infected insect cells. Purified
VP4 is a soluble, elongated monomer, as determined by analytical
ultracentrifugation. Trypsin cleaves purified VP4 at a number of sites
that are protected on the virion and yields a heterogeneous group of
protease-resistant cores of VP5*. The most abundant tryptic VP5* core
is trimmed past the N terminus associated with activation for virus
entry into cells. Sequential digestion of purified VP4 with
chymotrypsin and trypsin generates homogeneous VP8* and VP5* cores
(VP8CT and VP5CT, respectively), which have the authentic trypsin
cleavages in the activation region. VP8CT is a soluble monomer composed
primarily of Dehydrating diarrhea caused by
rotavirus infection kills an estimated 600,000 children annually
(2). The entry apparatus of rotavirus, consisting
of the spike protein, VP4, and the outer capsid glycoprotein, VP7, is
an important target of preventive and therapeutic interventions. VP4
and VP7 make up the outer capsid of the triple-layered, nonenveloped,
icosahedral rotavirus virion and are the targets of neutralizing and
protective antibodies against rotavirus (26). The outer
capsid is shed during entry, a poorly understood process that delivers
the transcriptionally active, 660-Å double-layered particle across a
lipid bilayer and into the cytoplasm.
VP4 has a central role in cell entry by rotavirus. Efficient
infectivity of rotavirus in cell culture requires trypsin cleavage of
VP4 into two fragments, VP5* and VP8*, both of which remain associated
with the virion (7, 12). Activation of rotavirus for
membrane interaction and infectivity has been mapped to a specific
cleavage site after residue R247 of VP4 (3, 15). The VP8*
trypsin cleavage product contains the viral hemagglutinin (HA)
(13); the VP5* fragment contains an internal hydrophobic region that has been linked to the ability of activated rotavirus virions to permeabilize membranes (9, 11). VP5* has also been implicated in the binding of sialic acid-independent strains of
rotavirus to cells (40).
Image reconstructions from electron cryomicroscopy of trypsinized
rotavirus particles demonstrate that VP4 forms dimeric spikes with lobed heads (36, 39). An additional domain of VP4 is buried beneath the VP7 shell and interacts extensively with the underlying VP6 layer (36, 39). Reconstructions of
rotavirus virions bound by Fabs recognizing VP8* or VP5* show that a
VP8* epitope is located in the heads of the spikes and that an epitope in the internal hydrophobic region of VP5* is located just proximal to
the heads (K. A. Dryden, M. Tihova, A. R. Bellamy, H. Greenberg, and M. Yeager, Abstr. Seventh Int. Symp. Double-Stranded RNA
Viruses, abstr. P2-15, 2000).
This work describes the purification and characterization
of recombinant rhesus rotavirus (RRV) VP4 expressed in
insect cells. It describes a proteolysis-triggered conformational
change in the VP5* region of VP4 that probably mimics trypsin-induced
rearrangements during virus activation. The proteolytic mapping of VP4
provides sequence-specific structural information, which complements
electron cryomicroscopy data and defines targets for high-resolution
structural studies.
Antibodies and virus strains.
Monoclonal antibodies HS1 and
HS2 were produced as mouse ascites fluids. HS1 recognizes a
nonneutralizing epitope on VP8*, and HS2 recognizes a nonneutralizing
epitope on VP5* (28). The recombinant baculovirus that
expresses RRV VP4 was constructed by Erich Mackow and has been
previously described (21).
Insect cell culture and baculovirus cultivation.
The
recombinant baculovirus was propagated in Sf9 insect cells with
Hinks' TMN FH insect cell medium (JRH Biosciences)
supplemented with 10% fetal bovine serum (HyClone) and in Sf900II
insect cell medium (Gibco-BRL). Virus titration, amplification, and
storage were performed as previously described (38). For
production of recombinant VP4, Sf9 insect cells were infected with
recombinant baculovirus at a multiplicity of infection of 0.4, maintained in spinner flasks at 28°C, and harvested by centrifugation
at 72 to 86 h postinfection.
Purification of VP4.
Recombinant baculovirus-infected cell
pellets were lysed by freezing and then thawed in a solution
containing 75 mM Tris (pH 8.0), 100 mM NaCl, 2 mM
EDTA, 7.5% glycerol, 2.5 mM benzamidine, and 1 mM phenylmethylsulfonyl
fluoride (PMSF). The lysate was clarified by centrifugation at
235,400 × g for 2 h. The clarified insect cell lysate was
diluted with 19 volumes of 20 mM Tris (pH 8.0)-10 mM NaCl-1 mM
EDTA-0.5 mM benzamidine. Proteins in the diluted lysate were bound to
Fast-flow DEAE Sepharose (Amersham-Pharmacia Biotech) and eluted with
an NaCl gradient. Fractions containing VP4 were identified by Western
blotting with monoclonal antibodies HS1 and HS2 and pooled. Pooled
fractions were concentrated and exchanged into a buffer containing less
than 20 mM NaCl using a Centricon-plus 80 ultrafiltration unit (Amicon,
Inc.). The exchanged sample was bound to a 20 HQ anion-exchange column
(PerSeptive Biosystems) and eluted with an NaCl gradient. Fractions
containing VP4 were pooled and concentrated by ultrafiltration.
Finally, VP4 was fractionated on a Hi-Load 16/60 Superdex 200 gel
filtration column (Amersham-Pharmacia Biotech) equilibrated in 20 mM
Tris (pH 8.0)-100 mM NaCl-1 mM EDTA (TNE). DEAE and Superdex 200 chromatography were performed on an FPLC system
(Amersham-Pharmacia Biotech). 20 HQ chromatography was performed on a
BioCAD Sprint chromatography system (PerSeptive Biosystems).
Generation of purified VP8CT and VP5CT from VP4.
A 1.1-mg/ml
solution of purified VP4 in TNE was made 4.2 µg/ml in TLCK
(1-chloro-3-tosylamido-7-amino-2-heptanone)-treated chymotrypsin
(Worthington Biochemical) and incubated for 30 min at 37°C. The
solution was briefly chilled on ice. TPCK
[L-(tosylamido-2-phenyl) chloromethyl ketone]-treated
trypsin (Worthington Biochemical) was added to 3.6 µg/ml, and the
solution was incubated for an additional hour at room temperature. The
digestion was stopped by the addition of PMSF (Sigma) to 1 mM, followed
by incubation on ice for 10 min and the addition of benzamidine to 2.5 mM. In some preparations, the sample was passed over a
benzamidine-Sepharose column (Amersham-Pharmacia Biotech) prior to the
addition of soluble protease inhibitors. The stopped digest was
concentrated with a Centricon 10 ultrafiltration unit (Amicon). The
resulting fragments were separated by gel filtration using a Superdex
200 HR 10/30 column (Amersham-Pharmacia Biotech) that had been
equilibrated in TNE. Fractions in the main peaks containing
well-separated VP5* and VP8* protease-resistant cores were
identified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and pooled separately. Stocks of trypsin and chymotrypsin
were resuspended from a lyophilized powder to 5 mg/ml in 1 mM HCl
and used within 1 week of preparation. Trypsin and chymotrypsin stock solutions were diluted 1:200 in 20 mM Tris-Cl (pH 8.0)-100 mM NaCl-2
mM CaCl2 immediately before use. PMSF was
prepared as a 100 mM stock solution in methanol. For small-volume
digestions, the PMSF stock was diluted with TNE immediately before
addition to each reaction mixture. The above is an optimized protocol. Minor variations used in some digestions are noted in the text and
figure legends.
Analytical ultracentrifugation.
Samples for analytical
ultracentrifugation were microdialyzed against TNE using a 6,000- to
8,000-molecular-weight (MW) cutoff dialysis membrane (Spectrum Medical
Industries). The diasylate was used as a blank and as diluent for
centrifugation. Analytical centrifugation was performed using an Optima
XL-A analytical ultracentrifuge (Beckman Coulter) with an AN-60 Ti
rotor. Absorbance data were obtained at 280 nm with 10 replicates per
measurement. Centrifugation speeds were set based on preliminary
estimates of molecular masses and standard nomograms (31).
The attainment of equilibrium was confirmed by comparing absorbance
curves obtained at 6-h intervals.
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.16.7339-7350.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Proteolysis of Monomeric Recombinant Rotavirus
VP4 Yields an Oligomeric VP5* Core
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-sheets. VP5CT forms sodium dodecyl sulfate-resistant
dimers. These results suggest that trypsinization of rotavirus
particles triggers a rearrangement in the VP5* region of VP4 to yield
the dimeric spikes observed in icosahedral image reconstructions from
electron cryomicroscopy of trypsinized rotavirus virions. The
solubility of VP5CT and of trypsinized rotavirus particles suggests
that the trypsin-triggered conformational change primes VP4 for a
subsequent rearrangement that accomplishes membrane penetration. The
domains of VP4 defined by protease analysis contain all mapped
neutralizing epitopes, sialic acid binding residues, the heptad repeat
region, and the membrane permeabilization region. This biochemical
analysis of VP4 provides sequence-specific structural information that
complements electron cryomicroscopy data and defines targets and
strategies for atomic-resolution structural studies.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
where Ar is the absorbance at
radius x; A0,1 is the
absorbance of the monomer at the reference radius
x0; H is a constant to
account for the specific volume of the protein, the solvent density,
the angular velocity of the rotor, and the temperature; M is
the monomer MW; N is the stoichiometry of the association; K is the association constant; and E is the
baseline offset. A0,1 is constrained
to be greater than 0. Specific volumes of the proteins and the density
of TNE at 4°C were calculated based on amino acid composition and
published data (24).
2t, where r is the
radial position (in centimeters) of the square root of the second
moment of the sedimenting boundary of VP4 as determined by absorbance
at 280 nm,
is the rotor angular velocity (radians per second), and
t is the duration of sedimentation (in seconds). The
S value was converted to
S20,w (S at
20°C in water) using a TNE viscosity of 1.018 cP at 20°C and a
VP4-specific volume of 0.729 cm3/g at 20°C
(31). The viscosity and specific volume were calculated based on published data (24). For calculation of the
frictional ratio
(f/f0), the actual
(f) and minimal (f0)
frictional coefficients were calculated, as described previously
(17), based on the S20,w for VP4, an estimate of
hydration of 0.3 g of H2O/g of VP4, and the mass
spectrometry-determined MW of VP4. The axial ratio was estimated from
the frictional ratio based on published graphs (17).
CD spectroscopy. Samples for circular dichroism (CD) spectroscopy were buffer exchanged into 20 mM boric acid-NaOH (pH 8.0)-100 mM sodium fluoride by microdialysis. CD was measured with an Aviv model 62DS CD spectrometer using a 1-mm-path-length quartz cuvette. Measurements were obtained in 0.5-nm intervals from 200 to 250 nm with 12 replicates, a 1-nm bandwidth, and a 0.5-s measurement time at each wavelength. Total ellipticity was converted to mean residue molar ellipticity based on the measured concentration of samples recovered from the CD cuvette (as below). To obtain secondary-structure predictions, a ridge regression algorithm (a variant of the least-squares method) was used to fit the CD data to a linear combination of the CD spectra of 16 proteins with determined structures (30).
Quantitation of protein.
The concentrations of VP4, VP5CT,
and VP8CT were determined by spectrophotometry at 280 nm. Absorbances
were converted to concentrations using molar extinction coefficients of
95.3 × 103 M
1
cm
1 for VP4, 42.2 × 103 M
1
cm
1 for VP5CT, and 39.6 × 103 M
1
cm
1 for VP8CT. Extinction coefficients were
calculated based on the predicted amino acid sequences. For more
accurate quantitation of the samples used in CD spectroscopy, the
samples were diluted with 3 volumes of 8 M guanidine-HCl prior to spectrophotometry.
Amino acid sequencing. Protein fragments for N-terminal sequencing were separated by SDS-PAGE and electroblotted onto a Sequi-Blot polyvinylidene difluoride membrane (Bio-Rad). Coomassie blue-stained bands were excised, and the N-terminal sequence was obtained at the Tufts Protein Chemistry Facility (Boston, Mass.).
Mass spectrometry. Matrix-assisted laser desorption ionization (MALDI)-time of flight mass spectrometry for full-length VP4 and cross-linked VP5CT was performed at the W. M. Keck Foundation Biotechnology Resource Laboratory at Yale University using a sinapinic acid matrix. The sample was calibrated using bovine serum albumin as a standard. The accuracy of measurement is estimated to be ±0.2%. MALDI-time of flight mass spectrometry of protease cleavage fragments of VP4 was performed at the Tufts Protein Chemistry Facility.
Chemical cross-linking. VP5CT at a concentration of 2 mg/ml was exchanged into 20 mM HEPES (pH 7.0)-100 mM NaCl by microdialysis. Freshly prepared 5-mg/ml bis(sulfosuccinimidyl)suberate (BS3; Pierce Endogen) in 5 mM Na-citrate, pH 5.0, was added to a final concentration of 0.83 mg/ml, and the sample was incubated at room temperature for 30 min. A second equal amount of BS3 was added, and the sample was incubated for an additional 30 min. The cross-linking reaction was quenched by adding Tris-Cl, pH 7.5, to a final concentration of 222 mM. The cross-linked material was microdialyzed against 20 mM ammonium bicarbonate, pH 7.7, and divided into aliquots for SDS-PAGE and mass spectrometry.
Calibration of gel filtration columns.
Superdex 200 gel
filtration columns were calibrated using a set of globular protein
standards (Amersham-Pharmacia Biotech) consisting of ferritin (440 kDa), aldolase (158 kDa), ovalbumin (43 kDa), and RNase A (13.7 kDa).
Calibration curves were constructed by plotting
KAV versus ln(MW), where
KAV equals
(Ve
V0)/(Vt
V0).
Ve is the measured elution volume of the
markers. V0, the void volume of
the column, was determined by gel filtration of blue dextran, and
Vt, the total column volume, was specified
by the manufacturer (Amersham-Pharmacia Biotech).
Molecular biology and electrophoresis.
Plasmid DNA for
sequencing was prepared using Qiagen plasmid Midi kits. DNA
oligonucleotide primer synthesis and plasmid DNA sequencing were
performed by the Howard Hughes Medical Institute Biopolymer Facility
(Boston, Mass.). SDS-PAGE, Coomassie blue staining, electroblotting,
and Western blotting were performed using established techniques
(34). Sample buffer for SDS-PAGE contained 125 mM Tris-Cl
(pH. 6.8), 4% SDS, 1%
-mercaptoethanol, 40% glycerol, and
bromphenol blue.
Computation. DNA and amino acid sequence data were analyzed using the Lasergene suite of DNAstar sequence analysis software. Ultracentrifugation data were analyzed using Optima XL-A software version 3.0 (Beckman Instruments, Inc.) and Origin version 3.78 (Microcal Software, Inc). CD data were analyzed using CONTIN (30). Graphs were produced using Origin version 5.0 (Microcal Software, Inc.). Chromatograms were traced in Photoshop, version 6.0 (Adobe, Inc.), and scaled in Illustrator, version 8.0 (Adobe, Inc.).
Nucleotide sequence accession number. The RRV gene segment 4 cDNA sequence was submitted to GenBank and has been assigned accession number AY033150.
| |
RESULTS |
|---|
|
|
|---|
Sequencing of cloned RRV gene segment 4. The clone of RRV gene segment 4 that was used to make the recombinant baculovirus was sequenced. This clone contains 32 nucleotide changes and encodes 11 amino acid changes relative to a published RRV gene segment 4 sequence, which is based on direct sequencing of pooled RRV mRNA (22). Each amino acid change replaces the residue encoded by the published VP4 sequence with a residue found in the corresponding position in VP4 of rotavirus strains SA11 or YM (18, 19). The changes are as follows: S73 to T, Y132 to N, D311 to E, I338 to V, F421 to L, G445 to S, G446 to R, Y454 to N, L468 to F, Y519 to D, and Y690 to F.
Purification of VP4.
VP4 was purified from the supernatant of
a freeze-thaw lysate of recombinant baculovirus-infected Sf9 cells
using anion-exchange chromatography with DEAE Sepharose and 20 HQ Poros
resin followed by gel filtration chromatography through Superdex 200 beads (see Materials and Methods). Gel filtration chromatography (Fig.
1A) yielded a major peak of VP4 with a
KAV of 0.326, corresponding to an apparent
molecular mass of 111 kDa. A tiny additional peak, with a
KAV of 0.198, corresponding to an apparent
molecular mass of 249 kDa, was also seen. Although such higher
molecular mass peaks also contain VP4, they are very small. Their
formation is increased by denaturing procedures such as freezing and
thawing of the sample, and they revert to the 111-kDa peak upon repeat gel filtration of stored fractions (data not shown).
|
Analytical ultracentrifugation of purified VP4.
Equilibrium
analytical ultracentrifugation of VP4 was used to determine the mass of
VP4 independent of shape and charge and without disturbing noncovalent
interactions. Centrifugation of VP4 at three different starting
concentrations yielded absorbance-versus-radius distributions that fit
the theoretical distribution of an 86.0-kDa monomeric protein (Fig.
2A). Small systematic residuals near the bottom of the cell in the highest-concentration sample (shown in Fig.
2A) gave evidence of a slight tendency to self-associate. Models in
which the VP4 monomer was in equilibrium with a dimer (not shown) did
not provide a closer fit to the experimental data, suggesting that
aggregation accounts for the residuals.
|
Trypsin digestion of purified VP4.
A protease analysis of
soluble VP4 was undertaken to determine if purified VP4 was cleaved at
the sites associated with virus activation, to seek evidence for a
protease-induced structural rearrangement, and to obtain
protease-resistant cores corresponding to structural domains. Trypsin
initially cleaved VP4 to produce a fragment with a mass
spectrometry-determined molecular mass of 21.86 kDa (not shown,
although the minor boiled VP4 band seen in Fig. 5A results from
unintended cleavage at or near this site by trace protease). This
cleavage was complete by the time that digestion was stopped by adding
PMSF immediately after a 850-µg/ml solution of VP4 was made 2.5 µg/ml in trypsin. Edman degradation showed that trypsin initially
cleaved after R582 (N-terminal sequence, SVGSS) to produce a
fragment (designated VP5Tx in Fig. 3B)
with a predicted C terminus after R775, one residue
short of the predicted C terminus at L776. Therefore, while trypsin
efficiently cleaves virion-associated VP4 only in the activation region
(3), the most trypsin-sensitive site on purified VP4 is
within the VP5* region, after R582. Mass spectrometry of freshly
purified VP4 indicates that the cleavage after R775 likely occurred
prior to intentional trypsin digestion (described above).
|
Chymotrypsin digestion of purified VP4. Digestion of VP4 with chymotrypsin also produced cores of VP8* and VP5* (VP8C and VP5C) (Fig. 3A). The VP8C N terminus was A46 (N-terminal sequence, APVNW), and its mass spectrometry-determined molecular mass was 21.32 kDa, predicting a C terminus at L236 (Fig. 3B). Depending on the time of digestion (30 versus 210 min), VP5C had an N terminus at S239 (N-terminal sequence, SARN; VP5Ca in Fig. 3B) or at R247 (N-terminal sequence, RAQAN; VP5Cb in Fig. 3B). VP5Cb produced a broad and weak mass spectrometry peak with a maximum between 31.44 and 31.82 kDa, predicting a C terminus (or C termini) between L525 and F528. Therefore, unlike trypsin, chymotrypsin cut in the activation region of purified VP4 without trimming the N termini of the resulting VP5* cores beyond A248.
Trypsin cleavage of chymotryptic VP4 fragments. Trypsin cleaved the chymotryptic VP4 cores to form VP8CT and VP5CT (Fig. 3). The products of digestion with chymotrypsin for 30 min at 37°C followed by combined digestion with trypsin and chymotrypsin for 1 h at room temperature were subjected to further analysis. The VP8CT N terminus was at A46 (N-terminal sequence, APVN), demonstrating that trypsin had left the N terminus of VP8C intact. Although VP8CT had a slightly greater apparent molecular mass than that of VP8C by SDS-PAGE (Fig. 3A), mass spectrometry showed its true molecular mass to be 20.88 kDa (Fig. 3C), approximately 440 Da smaller than the molecular mass of VP8C. The anomalous SDS-PAGE mobility of VP8CT relative to that of VP8C was highly reproducible and probably reflects anomalous SDS binding or a retained secondary structure. The N-terminal sequencing and mass spectrometry data show that trypsin cleaved the 5 C-terminal residues from VP8C to yield VP8CT, which is predicted to have the authentic VP8* C terminus at R231 (3).
Edman degradation of VP5CT revealed a single N terminus at A248 (N-terminal sequence, AQAN) (Fig. 3B). VP5CT produced a broad and relatively weak mass spectrometry peak with a maximum at 31.73 kDa (Fig. 3C), predicting that it shares the VP5C C terminus (or C termini) between L525 and F528. Therefore, trypsin had trimmed 9 N-terminal residues from VP5Ca or 1 N-terminal residue from VP5Cb to yield VP5CT, which has the single authentic, entry-associated VP5* N terminus at A248 (Fig. 3). These data indicate that the potential trypsin cleavage site after K258 is more resistant to trypsin cleavage in VP5C than in intact purified VP4. Because VP8CT and VP5CT are relatively (though not completely) homogeneous and have the entry-associated trypsin cleavages in the activation region, these fragments were purified and analyzed further.Separation of VP8CT and VP5CT by gel filtration chromatography.
Gel filtration chromatography of VP4 fragments generated by
sequential digestion with chymotrypsin and trypsin produced two major
peaks (Fig. 4A). The major peak,
designated "8" in Fig. 4A, had a KAV
of 0.502, corresponding to an apparent molecular mass of 27.5 kDa.
SDS-PAGE showed that peak 8 fractions contained VP8CT (Fig. 4B). The
major peak designated "5" in Fig. 4A had a
KAV of 0.348, corresponding to an apparent
molecular mass of 90.1 kDa. SDS-PAGE showed that peak 5 fractions
contained VP5CT (Fig. 4B). A minor peak eluting before peak 5 had a
KAV of 0.225, corresponding to an apparent
molecular mass of 231 kDa, and also contained VP5CT by SDS-PAGE (Fig.
4B). Thus, VP5CT formed two peaks with unexpectedly high apparent
molecular masses, suggesting the presence of more than one oligomeric
form. The main VP5CT peak was substantially broader than the VP8CT
peak. The ratio of height to width at half-height was 2.4 × 10
3 A280
units/ml for VP5CT and 1.3 × 10
3
A280 units/ml for VP8CT (measured on a
chromatogram where both peaks are fully recorded). The broadening of
the VP5CT main peak suggests heterogeneity of VP5CT particle size or a
nonideal interaction of VP5CT with the size exclusion medium. Gel
filtration chromatography cleanly purified VP5CT and VP8CT from each
other (Fig. 5b).
|
|
Electrophoretic analyses of VP4, VP8CT, and VP5CT.
Electrophoretic experiments were undertaken to investigate the
oligomeric state of VP5CT (Fig. 5). Reducing SDS-PAGE of boiled VP4,
VP5CT, and VP8CT yielded major bands with apparent molecular masses of
86.0, 32.7, and 22.6 kDa, respectively (Fig. 5A). These apparent
molecular masses are within 2 kDa of the molecular masses determined by
mass spectrometry. Reducing SDS-PAGE of unboiled VP4 and VP8 produced
major bands with electrophoretic mobilities indistinguishable from
those seen with boiled samples, but reducing SDS-PAGE of unboiled VP5CT
yielded a major band with an apparent molecular mass of 57.0 kDa (Fig.
5A). Reduction of VP5CT by sample buffer containing 5%
-mercaptoethanol instead of 1%
-mercaptoethanol gave the same
result (not shown). Minor bands of unboiled VP5CT had apparent
molecular masses of 29.0 and 32.7 kDa, suggesting that boiling had
relatively little effect on the SDS-PAGE mobility of monomeric VP5CT.
These data indicate that VP5CT forms a dimer that is disrupted by
boiling in the presence of SDS and
-mercaptoethanol but not by
exposure to SDS and
-mercaptoethanol at room temperature.
Chemical cross-linking of VP5CT.
VP5CT was cross-linked
chemically by incubation with BS3, boiled in
reducing sample buffer, and separated by SDS-PAGE (Fig. 6). Monomeric cross-linked VP5CT
comigrated with the untreated VP5CT at an apparent molecular mass of
31.2 kDa. Major cross-linked species migrated with apparent molecular
masses of 65.2 and 137.2 kDa, indicating that a significant amount of
VP5CT had been cross-linked into dimers and tetramers. Faint bands with
apparent molecular masses of 95.2 and 177.2 kDa may represent small
amounts of trimer (or incompletely cross-linked tetramer) and hexamer,
respectively. A contaminant band can be seen in both sample lanes at
approximately 43 kDa, and a faint haze in the untreated VP5CT lane at
approximately 65 kDa may represent a non-cross-linked dimer. Mass
spectrometry of the cross-linked material detected 31.27-, 63.04-, 95.10-, and 126.8-kDa species. The cross-linking data are most
compatible with V5CT dimers self-associating under nondissociating
conditions into tetramers and, possibly, higher-order complexes.
|
Analytical ultracentrifugation of VP8CT and VP5CT. The oligomeric states of VP8CT and VP5CT were further assessed by equilibrium analytical ultracentrifugation. Centrifugation of VP8CT at three different starting concentrations yielded absorbance-versus-radius distributions that fit the theoretical distribution of a nonassociating monomeric protein with a molecular mass of 22.4 kDa (Fig. 2C). Residuals showed a small, random scatter.
Equilibrium ultracentrifugation of VP5CT at three different starting concentrations yielded absorbance-versus-radius distributions that fit the theoretical distribution of a 31.7-kDa protein that forms very tightly associated dimers that further pair to form tetramers with a dimer-dimer association constant of 5.1 (Fig. 2D). This model is consistent with the electrophoretic and cross-linking data presented above, and the residuals show a small, random scatter. Despite the very close fit of this model to the data, the theoretical distribution of a 31.8-kDa protein that trimerizes with an association constant of 3.2 × 105 also gives small residuals, though with a more systematic error (not shown).CD spectroscopy.
The secondary structure compositions of VP4,
VP5CT, and VP8CT were assessed by CD spectroscopy. The theoretical
spectra (Fig. 7) of proteins
with the compositions given in Table
1 closely match the observed spectra
(Fig. 7). The CD data indicate that VP4 and VP5CT have mixed structures
but that VP8CT is predominantly composed of a
-sheet. VP4 appears to
have a higher proportion of
-helix than does either VP8CT or VP5CT
(Table 1). Consistent with this observation, sequence-based structure
predictions suggest that the portions of VP4 that are missing from both
VP5CT and VP8CT (Fig. 3B) are rich in
-helix (19).
|
|
| |
DISCUSSION |
|---|
|
|
|---|
A number of viral structural proteins undergo entry-associated conformational changes. Influenza virus HA undergoes a dramatic pH-triggered conformational change to extend a fusion domain from a buried position to a viral-membrane-distal position (5). A drop in pH also triggers the tick-borne encephalitis virus E protein to rearrange from a homodimer to a homotrimer (1). After binding to its cell receptor, poliovirus loses VP4, an internal capsid protein generated by autolytic cleavage, and exposes a hydrophobic region of VP1 (16). The capsids of some nonenveloped plant viruses, such as tomato bushy stunt virus, expand in low-calcium environments (33).
Rotavirus undergoes at least one major entry-related conformational transition: uncoating upon calcium chelation in vitro (8) and upon cell entry (20). A recent biochemical analysis of purified VP7 demonstrated that the dissociation of VP7 trimers to monomers is the biochemical basis for calcium chelation-induced rotavirus uncoating (10). Trypsin cleavage of the rotavirus spike protein, VP4, into the VP8* and VP5* fragments is required for efficient and productive entry of rotavirus into cells (4). Therefore, it is likely that proteolysis primes VP4 for a specific, entry-associated conformational change.
We have described in this paper a biochemical and biophysical analysis of purified recombinant VP4. The goals of this analysis have been to define a protease-triggered, entry-associated conformational change in VP4, to obtain sequence-specific structural data on VP4, and to obtain the biochemical understanding of VP4 required for successful atomic-resolution structural studies.
Gel filtration chromatography and analytical ultracentrifugation demonstrate that purified, recombinant VP4 is a moderately elongated monomer, well behaved in solution (Fig. 1A and 2A and B). Image reconstructions from electron cryomicroscopy of rotavirus particles alone and complexed with VP4-specific Fabs provide convincing evidence that VP4 forms dimers on trypsinized rotavirus particles (29, 36, 39). These findings suggest that dimeric interactions of paired VP4 molecules on the virion probably require stabilization either through a molecular rearrangement induced by trypsin cleavage or through interactions with VP6 (middle capsid layer) or VP7 (outer capsid layer).
Arias and coworkers showed that, during trypsin activation of virus, VP4 is initially cleaved C terminal to R241 and then to R231 and R247 (3). Enhancement of infectivity is specifically associated with the relatively inefficient cleavage after R247. The other potential trypsin recognition sites on virion-associated VP4 are protected from cleavage (3). Further evidence for this activation pathway was provided by a mutational analysis in which VP4 cleavage after R247 (but not after R231 or R241) was required for the induction of cell-cell fusion by virus-like particles (15).
Trypsin cleavage of purified, soluble VP4 is much more extensive (Fig. 3). Trypsin whittles 3.3 kDa from the N terminus of VP8* and approximately 30 kDa from the C terminus of VP5*. These findings suggest that the N-terminal 3.3 kDa and the C-terminal 30 kDa of virion-associated VP4 are sequestered from protease or folded into protease-resistant structures as a direct or indirect consequence of interactions between VP4 and VP6 or VP7.
As summarized in Fig. 3, the most abundant tryptic core of the VP5* region of purified VP4 lacks the entry-associated N terminus at A248 due to preferential trypsin cleavage after K258. Chymotrypsin digestion of purified VP4 protects the site after K258 and allows subsequent specific trypsin cleavage C terminal to R247. VP8CT and VP5CT have the primary structure of the VP4 activation region found on entry-competent virions. Other investigators have found that chymotrypsin cleaves in the activation region of virion-associated VP4 (3) but that this cleavage results in only a transient (4) or minimal (3) increase in infectivity. Subsequent trypsin treatment of chymotrypsin-treated rotavirus results in full enhancement of infectivity (3).
VP8CT is a homogeneous monomer, which is folded into a relatively
detergent-resistant structure and is composed primarily of
-sheets
(Fig. 2C, 4A, 5, and 6C and Table 1). Reducing SDS-PAGE of unboiled
VP5CT indicates that it forms stable, SDS- and
-mercaptoethanol-resistant dimers (Fig. 5A). The absence of VP4
spikes from icosahedrally averaged electron cryomicroscopy-based image
reconstructions of uncleaved rotavirus virions suggests that cleavage
triggers a major rearrangement in VP4 to produce the dimeric spikes
observed on trypsinized virions (8a). The
cleavage-dependent dimerization of VP5CT may reflect the same
underlying molecular property.
Data obtained under nondissociating conditions indicate that VP5CT dimers weakly self-associate. Specifically, by size exclusion chromatography, VP5CT migrated in two relatively broad peaks at apparent molecular masses of 90.1 and 231 kDa (Fig. 4A); by native gel electrophoresis, VP5CT migrated in a broad band (Fig. 5B); and by IEF, VP5CT formed a smear between two main states (Fig. 5C). The broad main peak of VP5CT observed by size exclusion chromatography and the broad band observed by native gel electrophoresis may contain mixtures of self-associated states of VP5CT dimers in rapid equilibrium. Cross-linking VP5CT with BS3 under nondenaturing conditions yielded VP5CT dimers and tetramers as the major stabilized products (Fig. 6). The equilibrium distribution of VP5CT upon centrifugation is consistent with a weak pairing of dimers to form tetramers (Fig. 2D). The biochemical specificity and biological significance of the SDS-sensitive association between dimers is unclear.
Gel filtration chromatography of VP5C showed that it, too, had oligomerized (not shown). It is likely that dimerization of VP5C sequesters its potential trypsin cleavage site after K258 (Fig. 3B). This site must also be protected, but by a different mechanism, on virion-associated VP4, which does not require chymotrypsin predigestion for efficient trypsin activation. Possibly, the enforced proximity between paired VP4 monomers on the virion leads to rapid dimerization after trypsin cleavage at the more trypsin-sensitive sites C terminal to R241 and R231. This rapid dimerization would prevent cleavage after K258 and permit activation by subsequent specific trypsin cleavage C terminal to R247.
Activated forms of viral fusion proteins and viral particles are often insoluble. For example, both isolated influenza virus HA and intact influenza virions aggregate at the pH of membrane fusion (35). Poliovirus aggregates after binding to a soluble form of its receptor (16). The solubility of proteolytically produced VP5CT (Fig. 2D and 4A) and trypsinized rotavirus virions suggests that they may not be fully activated for membrane attack. Indeed, trypsinized rotavirus particles do not permeabilize liposomes until after they are uncoated by calcium chelation (25). Therefore, the conformational change in VP4 triggered by trypsin cleavage probably primes the molecule for a subsequent rearrangement that actually accomplishes membrane penetration.
In contrast to VP5CT produced proteolytically, VP5CT expressed directly as a glutathione S-transferase-tagged fusion protein in bacteria or as a histidine-tagged fusion protein in insect cells or bacteria is insoluble (data not shown). Proteolytic removal of the glutathione S-transferase tag did not yield soluble VP5CT (not shown). Other investigators have found that directly expressed VP5* constructs are mainly insoluble (personal communication, Erich Mackow) but that they selectively permeabilize liposomes (9). When expressed directly, influenza HA2 (the fusion domain of HA) folds in its activated, low-pH form (6). Thus, proteolytically produced, soluble VP5CT may be a metastable precursor of the directly expressed, insoluble form. Future studies will compare the membrane interactions of directly expressed and proteolytically produced VP5CT and will examine the possibility of a triggered transition between the two forms.
The protease analysis of purified VP4 defines structural domains that match previously defined functional regions. VP8CT contains the mapped VP8*-specific neutralizing-antibody escape mutations (14, 22, 27, 41), the minimal VP8* antigenic peptide (23), and the hemagglutination region (13). VP5CT contains the hydrophobic region associated with membrane interaction (9), the mapped VP5*-specific neutralization escape mutations (22, 27, 37), the minimal VP5* antigenic peptide (23), and a short heptad repeat region.
The protease mapping of VP4 provides sequence-specific data that can be correlated with the shape of the protein as seen by electron cryomicroscopy. For example, the N-terminal 5.0 kDa and the C-terminal 27.4 kDa of purified VP4 were digested by the combination of chymotrypsin and trypsin (Fig. 3B), but they are protected on virion-associated VP4 (3). Image reconstructions from electron cryomicroscopy of virion-associated VP4 show that approximately 30 kDa of each VP4 monomer is buried beneath the VP7 shell (36, 39). Thus, the protease-sensitive C-terminal 27.4 kDa of VP4 probably makes up a substantial proportion of this buried domain.
The dimerization of VP5CT suggests that it forms much of the dimeric stalk of the trypsinized VP4 spike. As VP8CT is monomeric (Fig. 2C), it probably makes up the heads of the VP4 spike, which make no dimeric contacts. VP8CT dissociates from VP5CT (Fig. 4A), while authentic VP8* remains associated with virions following trypsin activation. It is likely, therefore, that the 45 N-terminal residues of VP8*, which are missing from VP8CT, mediate its tight association with VP5*, even after trypsin cleavage. This basic arrangement is supported by images from electron cryomicroscopy of rotavirus particles complexed with Fabs recognizing VP8* and VP5* (K. A. Dryden, M. Tihova, A. R. Bellamy, H. Greenberg, and M. Yeager, Abstr. Seventh Int. Symp. Double-Stranded RNA Viruses, abstr. P2-15, 2000) (29).
Rotavirus provides an unusual opportunity to study cell entry by nonenveloped viruses. All of the known viral components involved in cell entry (cleaved and uncleaved triple-layered particles, double-layered particles, VP4, VP5*, VP7, and VP8*) have now been purified (intact or as protease-resistant cores) in substantial quantity as soluble and biochemically tractable entities. The purified outer capsid proteins undergo triggered, entry-associated conformational changes in simple in vitro systems: purified VP7 trimers dissociate upon calcium chelation (10) and purified VP4 monomers are proteolytically cleaved to yield VP5* dimers. Functional studies of the interactions of these proteins with each other and with membranes will help to define the mechanisms of virus activation and membrane penetration.
Finally, these experiments have defined tractable targets for atomic-resolution structural analysis of the rotavirus entry apparatus. In particular, the characterization of purified VP4 has provided the biochemical basis for nuclear magnetic resonance and X-ray crystallographic studies, which have recently yielded atomic-resolution structures of the VP8* core with and without bound sialic acid (unpublished data).
| |
ACKNOWLEDGMENTS |
|---|
We thank Marina Babyonyshev for her skillful technical assistance; Michael Berne of the Tufts Protein Chemistry Facility for N-terminal sequencing and mass spectrometry; Walter McMurray and Kathy Stone of the W. M. Keck Foundation Biotechnology Resource Laboratory for mass spectrometry; and Raymond Brown, Susanne Liemann, Andrea Carfi, and Mykol Larvie for helpful discussions.
This work was supported by National Institutes of Health grants K08 AI 001496 to P.R.D and CA-13202 to S.C.H and by a VA Merit Review grant to H.B.G. S.C.H. is an investigator in the Howard Hughes Medical Institute.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Laboratory of Molecular Medicine, Enders 673, Children's Hospital, 320 Longwood Ave., Boston, MA 02115. Phone: (617) 355-4795. Fax: (617) 738-0184. E-mail: dormitze{at}crystal.harvard.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Allison, S. L., J. Schalich, K. Stiasny, C. W. Mandl, C. Kunz, and F. X. Heinz. 1995. Oligomeric rearrangement of tick-borne encephalitis virus envelope proteins induced by an acidic pH. J Virol. 69:695-700[Abstract]. |
| 2. | Anonymous. 1999. Rotavirus vaccines. Wkly. Epidemiol. Rec. 74:33-38[Medline]. |
| 3. | Arias, C. F., P. Romero, V. Alvarez, and S. Lopez. 1996. Trypsin activation pathway of rotavirus infectivity. J. Virol. 70:5832-5839[Abstract]. |
| 4. |
Barnett, B. B.,
R. S. Spendlove, and M. L. Clark.
1979.
Effect of enzymes on rotavirus infectivity.
J. Clin. Microbiol.
10:111-113 |
| 5. | Bullough, P. A., F. M. Hughson, J. J. Skehel, and D. C. Wiley. 1994. Structure of influenza haemagglutinin at the pH of membrane fusion. Nature 371:37-43[CrossRef][Medline]. |
| 6. |
Chen, J.,
S. A. Wharton,
W. Weissenhorn,
L. J. Calder,
F. M. Hughson,
J. J. Skehel, and D. C. Wiley.
1995.
A soluble domain of the membrane-anchoring chain of influenza virus hemagglutinin (HA2) folds in Escherichia coli into the low-pH-induced conformation.
Proc. Natl. Acad. Sci. USA
92:12205-12209 |
| 7. |
Clark, S. M.,
J. R. Roth,
M. L. Clark,
B. B. Barnett, and R. S. Spendlove.
1981.
Trypsin enhancement of rotavirus infectivity: mechanism of enhancement.
J. Virol.
39:816-822 |
| 8. | Cohen, J., J. Laporte, A. Charpilienne, and R. Scherrer. 1979. Activation of rotavirus RNA polymerase by calcium chelation. Arch. Virol. 60:177-186[CrossRef][Medline]. |
| 8a. |
Crawford, S. E.,
S. K. Mukherjee,
M. K. Estes,
J. A. Lawton,
A. L. Shaw,
R. F. Ramig, and B. V. Prasad.
2001.
Trypsin cleavage stabilizes the rotavirus VP4 spike.
J. Virol.
75:6052-6061 |
| 9. |
Denisova, E.,
W. Dowling,
R. LaMonica,
R. Shaw,
S. Scarlata,
F. Ruggeri, and E. R. Mackow.
1999.
Rotavirus capsid protein VP5* permeabilizes membranes.
J. Virol.
73:3147-3153 |
| 10. | Dormitzer, P. R., H. B. Greenberg, and S. C. Harrison. 2000. Purified recombinant rotavirus VP7 forms soluble, calcium-dependent trimers. Virology 277:420-428[CrossRef][Medline]. |
| 11. |
Dowling, W.,
E. Denisova,
R. LaMonica, and E. R. Mackow.
2000.
Selective membrane permeabilization by the rotavirus VP5* protein is abrogated by mutations in an internal hydrophobic domain.
J. Virol.
74:6368-6376 |
| 12. |
Estes, M. K.,
D. Y. Graham, and B. B. Mason.
1981.
Proteolytic enhancement of rotavirus infectivity: molecular mechanisms.
J. Virol.
39:879-888 |
| 13. | Fuentes-Panana, E. M., S. Lopez, M. Gorziglia, and C. F. Arias. 1995. Mapping the hemagglutination domain of rotaviruses. J. Virol. 69:2629-2632[Abstract]. |
| 14. | Giammarioli, A. M., E. R. Mackow, L. Fiore, H. B. Greenberg, and F. M. Ruggeri. 1996. Production and characterization of murine IgA monoclonal antibodies to the surface antigens of rhesus rotavirus. Virology 225:97-110[CrossRef][Medline]. |
| 15. |
Gilbert, J. M., and H. B. Greenberg.
1998.
Cleavage of rhesus rotavirus VP4 after arginine 247 is essential for rotavirus-like particle-induced fusion from without.
J. Virol.
72:5323-5327 |
| 16. | Gomez Yafal, A., G. Kaplan, V. R. Racaniello, and J. M. Hogle. 1993. Characterization of poliovirus conformational alteration mediated by soluble cell receptors. Virology 197:501-505[CrossRef][Medline]. |
| 17. | Kyte, J. 1995. Structure in protein chemistry. Garland Publishing, Inc., New York, N.Y. |
| 18. | Lopez, S., C. F. Arias, J. R. Bell, J. H. Strauss, and R. T. Espejo. 1985. Primary structure of the cleavage site associated with trypsin enhancement of rotavirus SA11 infectivity. Virology 144:11-19[CrossRef][Medline]. |
| 19. |
Lopez, S.,
I. Lopez,
P. Romero,
E. Mendez,
X. Soberon, and C. F. Arias.
1991.
Rotavirus YM gene 4: analysis of its deduced amino acid sequence and prediction of the secondary structure of the VP4 protein.
J. Virol.
65:3738-3745 |
| 20. | Ludert, J. E., F. Michelangeli, F. Gil, F. Liprandi, and J. Esparza. 1987. Penetration and uncoating of rotaviruses in cultured cells. Intervirology 27:95-101[Medline]. |
| 21. |
Mackow, E. R.,
J. W. Barnett,
H. Chan, and H. B. Greenberg.
1989.
The rhesus rotavirus outer capsid protein VP4 functions as a hemagglutinin and is antigenically conserved when expressed by a baculovirus recombinant.
J. Virol.
63:1661-1668 |
| 22. |
Mackow, E. R.,
R. D. Shaw,
S. M. Matsui,
P. T. Vo,
M. N. Dang, and H. B. Greenberg.
1988.
The rhesus rotavirus gene encoding protein VP3: location of amino acids involved in homologous and heterologous rotavirus neutralization and identification of a putative fusion region.
Proc. Natl. Acad. Sci. USA
85:645-649 |
| 23. |
Mackow, E. R.,
M. Y. Yamanaka,
M. N. Dang, and H. B. Greenberg.
1990.
DNA amplification-restricted transcription-translation: rapid analysis of rhesus rotavirus neutralization sites.
Proc. Natl. Acad. Sci. USA
87:518-522 |
| 24. | McRorie, D. K., and P. J. Voelker. 1993. Self-associating systems in the analytical ultracentrifuge. Beckman Instruments, Fullerton, Calif. |
| 25. |
Nandi, P.,
A. Charpilienne, and J. Cohen.
1992.
Interaction of rotavirus particles with liposomes.
J. Virol.
66:3363-3367 |
| 26. |
Offit, P. A.,
G. Blavat,
H. B. Greenberg, and H. F. Clark.
1986.
Molecular basis of rotavirus virulence: role of gene segment 4.
J. Virol.
57:46-49 |
| 27. | Padilla-Noriega, L., S. J. Dunn, S. Lopez, H. B. Greenberg, and C. F. Arias. 1995. Identification of two independent neutralization domains on the VP4 trypsin cleavage products VP5* and VP8* of human rotavirus ST3. Virology 206:148-154[CrossRef][Medline]. |
| 28. |
Padilla-Noriega, L.,
R. Werner-Eckert,
E. R. Mackow,
M. Gorziglia,
G. Larralde,
K. Taniguchi, and H. B. Greenberg.
1993.
Serologic analysis of human rotavirus serotypes P1A and P2 by using monoclonal antibodies.
J. Clin. Microbiol.
31:622-628 |
| 29. | Prasad, B. V., J. W. Burns, E. Marietta, M. K. Estes, and W. Chiu. 1990. Localization of VP4 neutralization sites in rotavirus by three-dimensional cryo-electron microscopy. Nature 343:476-479[CrossRef][Medline]. |
| 30. | Provencher, S. W., and J. Glockner. 1981. Estimation of globular protein secondary structure from circular dichroism. Biochemistry 20:33-37[CrossRef][Medline]. |
| 31. | Ralston, G. 1993. Introduction to analytical ultracentrifugation. Beckman Instruments, Fullerton, Calif. |
| 32. | Righetti, P. G., and J. W. Drysdale. 1974. Isoelectric focusing in gels. J. Chromatogr. 98:271-321[CrossRef][Medline]. |
| 33. | Robinson, I. K., and S. C. Harrison. 1982. Structure of the expanded state of tomato bushy stunt virus. Nature 297:563-568[CrossRef]. |
| 34. | Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. |
| 35. |
Sato, S. B.,
K. Kawasaki, and S. Ohnishi.
1983.
Hemolytic activity of influenza virus hemagglutinin glycoproteins activated in mildly acidic environments.
Proc. Natl. Acad. Sci. USA
80:3153-3157 |
| 36. | Shaw, A. L., R. Rothnagel, D. Chen, R. F. Ramig, W. Chiu, and B. V. Prasad. 1993. Three-dimensional visualization of the rotavirus hemagglutinin structure. Cell 74:693-701[CrossRef][Medline]. |
| 37. |
Taniguchi, K.,
W. L. Maloy,
K. Nishikawa,
K. Y. Green,
Y. Hoshino,
S. Urasawa,
A. Z. Kapikian,
R. M. Chanock, and M. Gorziglia.
1988.
Identification of cross-reactive and serotype 2-specific neutralization epitopes on VP3 of human rotavirus.
J. Virol.
62:2421-2426 |
| 38. | Willis, S. H., C. Peng, M. Ponce de Leon, A. V. Nicola, A. H. Rux, G. H. Cohen, and R. J. Eisenberg. 1998. Expression and purification of secreted forms of HSV glycoproteins from baculovirus-infected insect cells. In S. M. Brown, and A. R. McLean (ed.), Methods in molecular medicine: herpes simplex virus protocols, vol. 10. Humana Press, Inc., Totowa, N.J. |
| 39. | Yeager, M., J. A. Berriman, T. S. Baker, and A. R. Bellamy. 1994. Three-dimensional structure of the rotavirus haemagglutinin VP4 by cryo-electron microscopy and difference map analysis. EMBO J. 13:1011-1018[Medline]. |
| 40. |
Zarate, S.,
R. Espinosa,
P. Romero,
E. Mendez,
C. F. Arias, and S. Lopez.
2000.
The VP5 domain of VP4 can mediate attachment of rotaviruses to cells.
J. Virol.
74:593-599 |
| 41. |
Zhou, Y. J.,
J. W. Burns,
Y. Morita,
T. Tanaka, and M. K. Estes.
1994.
Localization of rotavirus VP4 neutralization epitopes involved in antibody-induced conformational changes of virus structure.
J. Virol.
68:3955-3964 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»